Our Vision

to relieve patient suffering and enhance lives

Using our novel R&D platform for the advancement of life-changing medicines, we focus on developing and commercializing treatments for neurological and endocrine related disorders.

Learn More

Tardive Dyskinesia

is an involuntary movement disorder

We have developed the first FDA-approved treatment for adults with tardive dyskinesia, an involuntary movement disorder associated with prolonged use of dopamine receptor blocking agents.

Learn More

Endometriosis and Uterine Fibroids

Not all patients suffer the same way

In our collaboration with AbbVie for women’s health, we have a novel, oral treatment approved in the United States for the management of moderate to severe endometriosis pain and another therapy to manage heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Under the collaboration, a treatment is also being investigated for the management of polycystic ovary syndrome.

Learn More


Is a chronic and progressive neurodegenerative disease

We have the first U.S. FDA-approved once-daily add-on therapy for patients with Parkinson’s disease experiencing "off" episodes. In collaboration with Voyager Therapeutics, we are also developing an innovative gene therapy for the treatment of Parkinson’s disease.

Learn More

Congenital Adrenal Hyperplasia

is a genetic disorder that requires lifelong care

We are investigating a novel treatment for the management of classic congenital adrenal hyperplasia, a rare disorder that causes serious acute and long-term clinical problems beginning at birth.

Learn More